ClinicalTrials.gg
Drug

Elranatamab clinical trials

Also written Elrexfio and PF-06863135.

studies test it
37
open now
26
in phase 3
5
first study started
2017

How each study uses elranatamab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the elranatamab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
14 Aug 2023 · ELREXFIO · BLA 761345 (FDA, Drugs@FDA)
European Union
7 Dec 2023 · Elrexfio · EMEA/H/C/005908 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Elranatamab
29
Elranatamab (PF-06863135)
4

Brand

Elrexfio
8

Development codes

PF-06863135
7
PF-0686313
1

Studies by the year they started

37 studies that test it; most in 2025 (10)

Studies that test elranatamab, by start year
YearStudies
20171
20216
20222
20233
20247
202510
20268

By phase

A phase 1/2 study counts in both.

Phase 1
8
Phase 2
23
Phase 3
5
Phase 4
2
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 15 · Other 22

Pfizer (13) · Massachusetts General Hospital (3) · PETHEMA Foundation (2) · M.D. Anderson Cancer Center (2) · SCRI Development Innovations, LLC (2) · Nantes University Hospital (1) · European Myeloma Network B.V. (1) · Institute of Hematology & Blood Diseases Hospital, China (1)

Often tested with

Tested in the same studies.

Lenalidomide (3) · Dexamethasone (2) · Mezigdomide (2) · Daratumumab (2) · Iberdomide (1) · Isatuximab (1) · Autologous Dendritic Cell/Myeloma Fusion Vaccine (1) · Nirogacestat (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 9, 1 in phase 3

Studies that test elranatamab, phase 3 first.

Studies

Open first, then newest update. How each study uses elranatamab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 37

See all 37 studies that test elranatamab →

Given beside what is tested · 7 — elranatamab is usual care or a partner of the new treatment

Codes

What other systems call elranatamab · ClinicalTrials.gg INT002170

  • MeSH (NLM) C000731940elranatamabOne source NLM
  • UNII (FDA) L0HR9A577VELRANATAMABConfirmed FDA, NLM, Wikidata
  • Wikidata Q121549012elranatamab (Elrexfio)Confirmed FDA, NLM, Wikidata
  • NCI Thesaurus C146860ElranatamabOne source FDA
  • DrugBank DB15395One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.